{
    "2019-07-03": [
        [
            {
                "time": "2019-07-09",
                "original_text": "美年健康(002044.SZ)年报推10派0.531516元 股权登记日7月9日",
                "features": {
                    "keywords": [
                        "美年健康",
                        "年报",
                        "分红",
                        "股权登记日"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "希玛眼科大涨近35%，医药行业结构性投资机会值得关注",
                "features": {
                    "keywords": [
                        "希玛眼科",
                        "大涨",
                        "医药行业",
                        "投资机会"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-02",
                "original_text": "海外医药新闻发布2019/7/2【西南医药朱国广陈铁林团队】",
                "features": {
                    "keywords": [
                        "海外医药",
                        "新闻发布",
                        "西南医药",
                        "研究团队"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物:19H1业绩延续高增长,预防微卡获批在即",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "业绩增长",
                        "预防微卡",
                        "获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}